HK1209051A1 - A method of improving liver function - Google Patents

A method of improving liver function Download PDF

Info

Publication number
HK1209051A1
HK1209051A1 HK15109811.1A HK15109811A HK1209051A1 HK 1209051 A1 HK1209051 A1 HK 1209051A1 HK 15109811 A HK15109811 A HK 15109811A HK 1209051 A1 HK1209051 A1 HK 1209051A1
Authority
HK
Hong Kong
Prior art keywords
liver function
improving liver
improving
methazolamide
therapy
Prior art date
Application number
HK15109811.1A
Other languages
English (en)
Chinese (zh)
Inventor
Ken Walder
Guy Krippner
Geoff Nicholson
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of HK1209051A1 publication Critical patent/HK1209051A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HK15109811.1A 2012-05-24 2013-03-15 A method of improving liver function HK1209051A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US201261651335P 2012-05-24
US201261666574P 2012-06-29 2012-06-29
US201261666574P 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Publications (1)

Publication Number Publication Date
HK1209051A1 true HK1209051A1 (en) 2016-03-24

Family

ID=49622927

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109811.1A HK1209051A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Country Status (15)

Country Link
US (2) US20150150855A1 (enExample)
EP (1) EP2854807A4 (enExample)
JP (2) JP6360826B2 (enExample)
KR (1) KR20150023405A (enExample)
CN (2) CN104487073A (enExample)
BR (1) BR112014029308A2 (enExample)
CA (1) CA2874513A1 (enExample)
CO (1) CO7160082A2 (enExample)
HK (1) HK1209051A1 (enExample)
MX (1) MX362111B (enExample)
NZ (2) NZ702645A (enExample)
RU (1) RU2653478C2 (enExample)
SG (2) SG11201407787VA (enExample)
WO (1) WO2013173859A1 (enExample)
ZA (1) ZA201408704B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
ES2660170T3 (es) * 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction

Also Published As

Publication number Publication date
EP2854807A4 (en) 2016-03-16
MX362111B (es) 2019-01-07
CN109498623A (zh) 2019-03-22
SG11201407787VA (en) 2014-12-30
JP6412241B2 (ja) 2018-10-24
WO2013173859A1 (en) 2013-11-28
KR20150023405A (ko) 2015-03-05
RU2653478C2 (ru) 2018-05-08
ZA201408704B (en) 2018-07-25
SG10201705388XA (en) 2017-07-28
CO7160082A2 (es) 2015-01-15
MX2014014317A (es) 2015-08-10
US20150150855A1 (en) 2015-06-04
CA2874513A1 (en) 2013-11-28
RU2014152196A (ru) 2016-07-20
EP2854807A1 (en) 2015-04-08
JP2015517534A (ja) 2015-06-22
US20180333399A1 (en) 2018-11-22
JP6360826B2 (ja) 2018-07-18
NZ723206A (en) 2018-02-23
CN104487073A (zh) 2015-04-01
BR112014029308A2 (pt) 2017-06-27
NZ702645A (en) 2016-08-26
JP2018090589A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
WO2012062925A3 (en) Compounds and methods for treating pain
WO2013056148A3 (en) Scd1 antagonists for treating cancer
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
HK1202549A1 (en) Donepezil pamoate, preparation method and its use
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
HK1197159A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
WO2013117744A3 (en) Methods of treating fibrosis
WO2013098416A3 (fr) Composes anti-douleur
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
WO2014093999A3 (en) Alkaline drink
SG10201804034QA (en) Methods for treating hypotension
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3027049A4 (en) Treatment of beverages to reduce the effects of noxious constituents
WO2014062878A3 (en) Treatment of prostate cancer with tor kinase inhibitors
WO2013067531A3 (en) Methods of using microrna 195 in providing neuroprotection
WO2012138223A3 (en) Compounds and methods for altering activin receptor-like kinase signalling
PT2770979E (pt) Composição de reticulação melhorada administrada por iontoforese, útil para o tratamento do queratocone
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
MX362111B (es) Un metodo para mejorar la funcion hepatica.
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject